In vitro lung models refer to experimental models that mimic the structures and functions of the human lung. They are utilized to study basic lung biology, disease mechanisms as well as test the efficacy and toxicity of potential therapeutics. Lung models replicate key characteristics of the organ such as its 3D architecture, ability to perform gas exchange and response to toxicants. Various cell types are employed including alveolar epithelial and endothelial cells that form the air-blood barrier. These models provide a reduced animal alternative for drug development and chemical safety assessment applications.
The global in vitro lung model market is estimated to be valued at US$ 279.8 Mn in 2024 and is expected to exhibit a CAGR of 14% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Rising respiratory diseases such as asthma, lung cancer and chronic obstructive pulmonary disease (COPD) constitute a major driver for the in vitro lung model market. As per the Global Burden of Disease Study, lower respiratory infections and COPD accounted for over 4 million deaths worldwide in 2017. This growing disease prevalence has intensified the need for effective drugs. Conventional animal models often poorly predict human responses, necessitating improved predictive preclinical models. In vitro lung models better emulate the structural and functional properties of the human lungs compared to animal models. This facilitates more clinically relevant evaluation of candidate therapeutics. In addition, regulatory mandates favoring alternative testing methods are contributing to market growth. For example, the EU banned animal testing of ingredients in cosmetic products from 2013.
Strength: The global in vitro lung model market has strong research and development initiatives. Three growing pharmaceutical companies are investing heavily in research to develop new lung disease treatment options. Advancements in cell and tissue culture technologies allow more realistic in vitro lung models to be developed.
Weakness: Developing human-relevant in vitro lung models remain technically challenging. Complex lung structure and physiology is difficult to fully replicate in vitro. High costs involved in developing and maintaining complex 3D tissue models.
Opportunity: Rising incidence of respiratory diseases worldwide increases the need for improved drug development and safety testing methods. In vitro lung models help reduce reliance on animal testing. Growing biotech sector investments in developing personalized medicine using patient-derived cells open new opportunities.
Threats: Stringent regulatory norms for validating new in vitro models delay their commercial adoption. Ethical concerns over using human cells and tissues can affect public perception. Intense competition exists from alternative testing methods.
The global in vitro lung model market is expected to witness high growth over the forecast period driven by rising research in respiratory disease treatment.
Regional analysis: North America accounts for the largest share of the global in vitro lung model market currently. Major market players such as Epithelix, Emulate, Lonza etc. are based in the US and receive strong support from NIH and other funding agencies. However, Asia Pacific region is poised to grow at the fastest rate during the forecast period. Countries like China and Japan are strongly promoting development of domestic biotech industry through initiatives such as Made in China 2025. Globally renowned contract research organizations are also establishing manufacturing and R&D centers in Asia to cater to the growing research demands.
Key players operating in the global in vitro lung model market are Epithelix, MATTEK, Lonza, Emulate, AlveoliX AG, Nortis, CN Bio Innovations Ltd, MIMETAS, InSphero, ATTC Global, Tissuse GmbH and Cn Bio Innovations Limited.
Get More Insights On This Topic: https://www.newsanalyticspro.com/in-vitro-lung-model-market-analysis-growth-forecast-outlook-2023-2030/